申请人:ELI LILLY AND COMPANY
公开号:EP0839807A1
公开(公告)日:1998-05-06
A process for preparing intermediates and benzoquinolin-3-one pharmaceuticals, of the following formula I:
wherein R1 represents:
2-nitrophenyl, 4-nitrophenyl, 2-cyanophenyl, 4-cyanophenyl, 2-nitronaphthyl, 4-nitronaphthyl, 2-cyanonaphthyl, 4-cyanonaphthyl, 2-quinolinyl, 4-quinolinyl, 7-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl, 8-isoquinolinyl, 2-quinoxalinyl, 2-benzothiazolyl, 3-1H-indazolyl, 2-benzoxazolyl, 3-1,2-benzisothiazolyl, 2-pyridinyl, 4-pyridinyl, 2-pyrazinyl, 2-naphtho[2,3-d]thiazolyl, 2-naphto[1,2-d]thiazolyl, 9-anthryl, 2-thiazolyl, 2-benzimidazolyl, 1-benz[g]isoquinolinyl, 8-benz[g]isoquinolinyl, 5-1H-tetrazolyl, 2-quinazolinyl, 2-thiazolo[4,5-b]pyridinyl, 4-10H-pyridazino[3,2-b]-2-quinazolinyl, 2-1,4-benzodioxinyl, 2-triazine, 2-benzoxazine, 4-benzoxazine, 2-purine or 8-purine.
Such pharmaceuticals are effective in treating conditions consequent on 5α-reductase.
一种制备下式 I 的中间体和苯并喹啉-3-酮药物的工艺:
其中 R1 代表
2-硝基苯基,4-硝基苯基,2-氰基苯基,4-氰基苯基,2-硝基萘基,4-硝基萘基,2-氰基萘基,4-氰基萘基,2-喹啉基,4-喹啉基,7-喹啉基、1-isoquinolinyl, 3-isoquinolinyl, 8-isoquinolinyl, 2-quinoxalinyl, 2-benzothiazolyl, 3-1H-indazolyl, 2-benzoxazolyl, 3-1,2-benzisothiazolyl, 2-pyridinyl, 4-pyridinyl、2-吡嗪基、2-萘并[2,3-d]噻唑基、2-萘并[1,2-d]噻唑基、9-蒽基、2-噻唑基、2-苯并咪唑基、1-苯并[g]异喹啉基、8-苯并[g]异喹啉基、5-1H-四唑基2-喹唑啉基、2-噻唑并[4,5-b]吡啶基、4-10H-哒嗪并[3,2-b]-2-喹唑啉基、2-1,4-苯并二恶烷基、2-三嗪、2-苯并恶嗪、4-苯并恶嗪、2-嘌呤或 8-嘌呤。
这些药物可有效治疗 5α 还原酶引起的疾病。